

Company registration number 217978 (Eire)

**WARD CHEMISTS LIMITED**  
**ABRIDGED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

# WARD CHEMISTS LIMITED

## CONTENTS

---

	<b>Page</b>
Directors' declaration	1
Balance sheet	2 - 3
Notes to the financial statements	4 - 8

---

# WARD CHEMISTS LIMITED

## DIRECTORS' DECLARATION ON UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025

---


In relation to the financial statements set out on pages 2 to 8:

- The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgments underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.
- The directors confirm that they have made available to DBA Accountants Limited, all the company's accounting records and provided all the information necessary for the compilation of the financial statements.
- The directors confirm that to the best of their knowledge and belief, the accounting records reflect all transactions of the company for the year ended 30 June 2025.

On behalf of the board



Gregory Ward  
Director



Justin Ward  
Director

24 February 2026

# WARD CHEMISTS LIMITED

## BALANCE SHEET

AS AT 30 JUNE 2025

---

	Notes	2025		2024	
		€	€	€	€
<b>Fixed assets</b>					
Tangible assets	4		129,294		157,834
<b>Current assets</b>					
Stocks	5	116,730		114,756	
Debtors	6	107,872		113,757	
Cash at bank and in hand		320,533		282,813	
		<u>545,135</u>		<u>511,326</u>	
<b>Creditors: amounts falling due within one year</b>	7	<u>(45,124)</u>		<u>(43,299)</u>	
<b>Net current assets</b>			<u>500,011</u>		<u>468,027</u>
<b>Net assets</b>			<u>629,305</u>		<u>625,861</u>
<b>Capital and reserves</b>					
Called up share capital presented as equity	8		147		147
Profit and loss reserves	9		629,158		625,714
<b>Total equity</b>			<u>629,305</u>		<u>625,861</u>

---

# WARD CHEMISTS LIMITED

## BALANCE SHEET (CONTINUED)

AS AT 30 JUNE 2025

---

We, as directors of Ward Chemists Limited, state that:

(a) The company is availing itself of the exemption from audit provided for by Chapter 15 of Part 6 of the Companies Act 2014.

(b) The company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied.

(c) The shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2).

(d) The directors acknowledge the obligations of the company, under the Companies Act 2014:

(i) to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year; and

(ii) to otherwise comply with the provisions of this Act relating to financial statements so far as they are applicable to the company.


(e) The company has relied on the specified exemption contained in section 352 Companies Act 2014; the company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with Financial Reporting Standard 102 'The Financial Statement Reporting Standard applicable in the UK and Republic of Ireland'.

The financial statements were approved by the board of directors and authorised for issue on 24 February 2026 and are signed on its behalf by:



Gregory Ward  
Director



Justin Ward  
Director

# WARD CHEMISTS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2025

---

### 1 Accounting policies

#### Company information

Ward Chemists Limited is a limited company domiciled and incorporated in Eire. The registered office is 4 Market Street, Monaghan, Co. Monaghan and it's company registration number is 217978. The principal activity during the year continued to be the retail sale of pharmaceutical products.

#### 1.1 Accounting convention

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), as adapted by Section 1A of FRS 102, and the requirements of the Companies Act 2014.

The financial statements are prepared in euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest €.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 1.2 Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

#### 1.3 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

Buildings Freehold	4% Straight Line
Fixtures, fittings & equipment	20% Straight Line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

#### 1.4 Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

#### 1.5 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

# WARD CHEMISTS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

---

### 1 Accounting policies

(Continued)

#### 1.6 Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### 1.7 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

##### **Basic financial liabilities**

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

#### 1.8 Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

##### **Current tax**

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

##### **Deferred tax**

Deferred taxation is provided on the liability method to take account of timing differences between the treatment of certain items for accounts purposes and for their treatment for tax purposes. Tax deferred or accelerated is accounted for in respect of all material timing differences. Deferred tax assets are recognised to the extent that they are regarded as recoverable.

#### 1.9 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

# WARD CHEMISTS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2025

### 2 Employees

The average monthly number of persons (including directors) employed by the company during the year was 8 (2024 - 8).

	2025 Number	2024 Number
Counter assistants	6	6
Pharmacist	1	1
Management	1	1
Total	<u>8</u>	<u>8</u>

### 3 Directors' remuneration

	2025 €	2024 €
Remuneration for qualifying services	<u>128,220</u>	<u>206,095</u>

### 4 Tangible fixed assets

	Buildings Freehold €	Fixtures, fittings & equipment €	Total €
<b>Cost</b>			
At 1 July 2024 and 30 June 2025	<u>269,184</u>	<u>297,967</u>	<u>567,151</u>
<b>Depreciation and impairment</b>			
At 1 July 2024	134,593	274,725	409,318
Depreciation charged in the year	<u>5,384</u>	<u>23,155</u>	<u>28,539</u>
At 30 June 2025	<u>139,977</u>	<u>297,880</u>	<u>437,857</u>
<b>Carrying amount</b>			
At 30 June 2025	<u>129,207</u>	<u>87</u>	<u>129,294</u>
At 30 June 2024	<u>134,591</u>	<u>23,243</u>	<u>157,834</u>

### 5 Stocks

	2025 €	2024 €
Finished goods and goods for resale	<u>116,730</u>	<u>114,756</u>

There is no material difference between the replacement cost of stocks and their balance sheet amounts.

# WARD CHEMISTS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

<b>6 Debtors</b>			<b>2025</b>	<b>2024</b>
			€	€
<b>Amounts falling due within one year:</b>				
Trade debtors			54,895	55,545
Other debtors			43,415	49,401
Prepayments			3,923	3,211
			<u>102,233</u>	<u>108,157</u>
Deferred tax asset			5,639	5,600
			<u>107,872</u>	<u>113,757</u>
			<u><u>107,872</u></u>	<u><u>113,757</u></u>
<b>7 Creditors: amounts falling due within one year</b>			<b>2025</b>	<b>2024</b>
			€	€
Trade creditors			27,215	25,639
Other creditors including tax and social insurance			17,560	11,686
Accruals			349	5,974
			<u>45,124</u>	<u>43,299</u>
			<u><u>45,124</u></u>	<u><u>43,299</u></u>
<b>8 Called up share capital</b>			<b>2025</b>	<b>2024</b>
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
	Number	Number	€	€
<b>Ordinary share capital</b>				
<b>Authorised equity</b>				
Ordinary shares of €1.269738 each	1,000,049	1,000,049	1,269,800	1,269,800
	<u>1,000,049</u>	<u>1,000,049</u>	<u>1,269,800</u>	<u>1,269,800</u>
<b>Issued and fully paid</b>				
Ordinary shares of €1.269738 each	116	116	147	147
	<u>116</u>	<u>116</u>	<u>147</u>	<u>147</u>
	<u><u>116</u></u>	<u><u>116</u></u>	<u><u>147</u></u>	<u><u>147</u></u>
<b>9 Profit and loss reserves</b>			<b>2025</b>	<b>2024</b>
			€	€
At the beginning of the year			625,714	669,135
Profit/(loss) for the year			3,444	(43,421)
			<u>629,158</u>	<u>625,714</u>
At the end of the year			<u>629,158</u>	<u>625,714</u>
			<u><u>629,158</u></u>	<u><u>625,714</u></u>

# WARD CHEMISTS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2025

---

### 10 Directors' transactions

Transactions in relation to loans to/(from) directors during the year are outlined in the table below:

Description	% Rate	Opening balance €	Amounts advanced €	Amounts repaid €	Closing balance €
Gregory Ward - Repayable on demand	-	6,020	6,001	(17,610)	(5,589)
		<u>6,020</u>	<u>6,001</u>	<u>(17,610)</u>	<u>(5,589)</u>
		<u><u>6,020</u></u>	<u><u>6,001</u></u>	<u><u>(17,610)</u></u>	<u><u>(5,589)</u></u>

### 11 Approval of financial statements

The directors approved the financial statements on 24 February 2026.